COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.


In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to Blood, Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273 / administration & dosage*
  • Adult
  • Aged
  • Aged, 80 and over
  • BNT162 Vaccine / administration & dosage*
  • COVID-19* / immunology
  • COVID-19* / mortality
  • COVID-19* / prevention & control
  • Female
  • Hematologic Neoplasms* / immunology
  • Hematologic Neoplasms* / mortality
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2 / immunology*


  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine